Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 12:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,912 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bleeding Disorder Clear all
Not listed Phase 4 Interventional

Preventing Inhibitor Recurrence Indefinitely

NCT04621916
View directory record Official record
Conditions
Hemophilia A, Immune Tolerance
Interventions
FVIII, Emicizumab
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
0 Years to 12 Years · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 21, 2026, 12:40 PM EDT
Terminated Phase 1 Interventional

12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder

NCT00004058
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Precancerous/Nonmalignant Condition
Interventions
tetradecanoylphorbol acetate
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 26, 2010 · Synced Oct 21, 2026, 12:40 PM EDT
Completed No phase listed Observational

A Study of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants

NCT04394234
View directory record Official record
Conditions
Uterine Hemorrhage
Interventions
Direct oral anticoagulant (DOACs), Warfarin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
961,985 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 21, 2026, 12:40 PM EDT
Terminated Phase 4 Interventional Results available

Does An Abnormal PFA 100 Predict Bleeding After Renal Biopsy?

NCT00334204
View directory record Official record
Conditions
Kidney Failure, Acute, Kidney Failure, Chronic, Blood Platelet Disorders, Hemorrhage
Interventions
measuring Platelet Function Analyser-100 (PFA-100) platelet function before kidney biopsy
Device
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Oct 21, 2026, 12:40 PM EDT
Completed Phase 1 Interventional

Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects

NCT02490787
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A
Interventions
Concizumab, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
8
States / cities
Torrance, California • Indianapolis, Indiana • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 21, 2026, 12:40 PM EDT
Completed No phase listed Observational

Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)

NCT02953704
View directory record Official record
Conditions
MPN (Myeloproliferative Neoplasms)
Interventions
Not listed
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
114
States / cities
Huntsville, Alabama • Tempe, Arizona • Tucson, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated May 13, 2022 · Synced Oct 21, 2026, 12:40 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Factor IX Gene Therapy Study (FIX-GT)

NCT03369444
View directory record Official record
Conditions
Hemophilia B
Interventions
FLT180a
Biological
Lead sponsor
University College, London
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Oct 21, 2026, 12:40 PM EDT
Active, not recruiting Not applicable Interventional

LEADERS FREE II: BioFreedom™ Pivotal Study

NCT02843633
View directory record Official record
Conditions
Acute Coronary Syndrome, High Bleeding Risk
Interventions
BioFreedom™ Drug Coated Coronary Stent System, Antiplatelet Drug
Device · Drug
Lead sponsor
Biosensors Europe SA
Industry
Eligibility
Not listed
Enrollment
1,203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
39
States / cities
Huntsville, Alabama • Hot Springs, Arkansas • La Jolla, California + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 21, 2026, 12:40 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Sulcular Bristle Tip Technique (SBTT) With an Electric Toothbrush

NCT04427397
View directory record Official record
Conditions
Gum Bleed
Interventions
Sulcular Bristle Tip Technique (SBTT)
Other
Lead sponsor
Tufts University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Oct 21, 2026, 12:40 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Indomethacin Germinal Matrix Hemorrhage/Intraventricular Hemorrhage (GMH/IVH) Prevention Trial

NCT00033917
View directory record Official record
Conditions
Intraventricular Hemorrhage (IVH), Bleeding in the Brain, Prematurity, Very Low Birth Weight Infants
Interventions
indomethacin, placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
Up to 6 Hours
Enrollment
630 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1989 – 2012
U.S. locations
3
States / cities
New Haven, Connecticut • Portland, Maine • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Oct 21, 2026, 12:40 PM EDT
Not yet recruiting Phase 3 Interventional

Restarting Anticoagulation After Traumatic Intracranial Hemorrhage

NCT04229758
View directory record Official record
Conditions
Hemorrhage, Intracranial Hemorrhages, Bleeding, Trauma
Interventions
Anticoagulants
Drug
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 21, 2026, 12:40 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Experimental Peri-implant Mucositis on Implant Sites That Were Previously Treated With or Without Implantoplasty

NCT06063876
View directory record Official record
Conditions
Peri-implant Mucositis, Peri-Implantitis
Interventions
Induction of experimental peri-implant mucositis, Resolution of experimental peri-implant mucositis
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 21, 2026, 12:40 PM EDT
Completed No phase listed Observational

Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS

NCT02190149
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
ADVATE (Antihemophilic Factor [Recombinant]), RIXUBIS (Coagulation Factor IX [Recombinant])
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
13 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
17
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Oct 21, 2026, 12:40 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing

NCT01280825
View directory record Official record
Conditions
Patients Undergoing Routine Health Care, Heart Diseases, Inflammatory Bowel Diseases, Autoimmune Disease, Inflammatory Disease, Blood Coagulation Disorders, Hepatitis C, Non-Metastatic Neoplasm
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 21, 2026, 12:40 PM EDT
Recruiting Phase 1 Interventional

Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability

NCT07053917
View directory record Official record
Conditions
Stroke, Chronic Stroke, Intracerebral Haemorrhage, Intracerebral Haemorrhage (ICH), Intracerebral Hemorrhage Basal Ganglia, Ischemic Stroke, Ischemic Stroke and Hemorrhagic Stroke, Hemiparesis After Stroke, Hemiplegia Following Ischemic Stroke, Hemiplegia and Hemiparesis, Hemiplegia and/or Hemiparesis Following Stroke, Middle Cerebral Artery Stroke
Interventions
Psilocybin (Usona Institute)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 21, 2026, 12:40 PM EDT
Completed Not applicable Interventional Results available

Clinical Trial of Factor XIII (FXIII) Concentrate

NCT00640289
View directory record Official record
Conditions
Hemophilia, Factor XIII Deficiency
Interventions
Fibrogammin P
Drug
Lead sponsor
Children's Hospital of Orange County
Other
Eligibility
Not listed
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 21, 2026, 12:40 PM EDT
Terminated No phase listed Observational

Change in Thrombin Generation Potential and Thromboelastography During the Menstrual Cycle

NCT00178542
View directory record Official record
Conditions
Von Willebrand Disease
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2013 · Synced Oct 21, 2026, 12:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Vitamin E for Extremely Preterm Infants

NCT01193270
View directory record Official record
Conditions
Infant, Newborn, Infant, Small for Gestational Age, Infant, Very Low Birth Weight, Infant, Premature, Intracranial Hemorrhages
Interventions
Vitamin E, Placebo
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 4 Hours
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
16
States / cities
Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2015 · Synced Oct 21, 2026, 12:40 PM EDT
Recruiting Not applicable Interventional

Safety, Feasibility, and Efficacy of Non-invasive Vagus Nerve Stimulation (nVNS) in the Treatment of Aneurysmal Subarachnoid Hemorrhage

NCT05103566
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Aneurysmal
Interventions
gammaCore
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 21, 2026, 12:40 PM EDT
Not listed No phase listed Observational

Safety of Oral Anticoagulants Registry

NCT02745054
View directory record Official record
Conditions
Blood Coagulation
Interventions
mgt of bleeding concerns/complications of oral anticoagulants
Other
Lead sponsor
Hospital Quality Foundation
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
9
States / cities
Birmingham, Alabama • Hartford, Connecticut • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 21, 2026, 12:40 PM EDT
Terminated Phase 3 Interventional Results available

Hemophilia Adult Prophylaxis Study: Factor VIII in Severe Hemophilia A

NCT01405742
View directory record Official record
Conditions
Severe Hemophilia A
Interventions
rF.VIII
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Oct 21, 2026, 12:40 PM EDT
Terminated Not applicable Interventional

Physiological Disturbances Associated With Neonatal Intraventricular Hemorrhage

NCT00665769
View directory record Official record
Conditions
Intraventricular Hemorrhage, Autoregulation
Interventions
Hypercapnia, Normocapnia
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Minute to 7 Days
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 21, 2026, 12:40 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773

NCT01395810
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia B
Interventions
nonacog beta pegol
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
13 Years to 70 Years · Male only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated May 9, 2018 · Synced Oct 21, 2026, 12:40 PM EDT
Completed No phase listed Observational

A Study to Compare the Risk of a Major Bleeding in Participants Who Received Blood Thinning Medications Following a Blood Clot

NCT03521908
View directory record Official record
Conditions
Venous Thromboembolism (VTE)
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
35,756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 28, 2022 · Synced Oct 21, 2026, 12:40 PM EDT